CDKN2B and atherosclerosis: Compared with the oe-NC group, the levels of IL-1β and TNF-ɑ in the oe-CDKN2B-AS1 group were significantly decreased (Figure 2D, p < 0.05), which ultimately suggested that CDKN2B-AS1 could inhibit the inflammatory response in atherosclerosis.